Vectura Loses U.K. Court Case Against GSK Over Patents
December 13 2018 - 8:21AM
Dow Jones News
By Adam Clark
Vectura Group PLC (VEC.LN) said Thursday that a U.K. court ruled
against it in a patent dispute with GlaxoSmithKline PLC
(GSK.LN).
The judgment related to a 2010 patent agreement between Vectura
and GSK over Ellipta-branded products for lung disease and
asthma.
Vectura said it was disappointed by the ruling and will consider
its options, including seeking permission to appeal. Vectura said
it doesn't believe the result will materially affect proceedings in
the U.S. related to the same patent agreement.
Shares at 1242 GMT were down 1.60 pence, or 2.2%, at 71.05
pence.
Write to Adam Clark at adam.clark@dowjones.com
(END) Dow Jones Newswires
December 13, 2018 08:06 ET (13:06 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
